Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors: A review of the literature

Oncology Nursing Forum

Volumn 41, Issue 6, 2014, Pages E343-E354

  Hershey, Denise Soltow ^a   Bryant, Ashley Leak ^b   Olausson, Jill ^c   Davis, Ellen D ^d   Brady, Veronica J ^e   Hammer, Marilyn ^f  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f NEW YORK UNIVERSITY   (United States)

Author keywords

Chemotherapy; Hyperglycemia; Neoplasm

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CHEMICALLY INDUCED; HUMAN; HYPERGLYCEMIA; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; HYPERGLYCEMIA; NEOADJUVANT THERAPY; NEOPLASMS;

EID: 84911490333     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/14.ONF.E343-E354     Document Type: Article

References (47)

1. Ali, N.A., O'Brien, J.M., Jr., Blum, W., Byrd, J.C., Klisovic, R.B., Marcucci, G., . . . Grever, M.R. (2007). Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer, 110, 96-102.
2. Barone, B., Yeh, H., Snyder, C., Peairs, K., Stein, K., Derr, R., ... Brancati, F. (2008). Long-term all-cause mortality in cancer patients with preexisting diabetis mellitus: A systematic review and meta-analysis. JAMA, 300, 2754-2764. doi:10.1001/jama.2008.824
3. Basaria, S. (2008). Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: An inconvenient truth. Journal of Andrology, 29, 534-539.
4. Basaria, S., Muller, D.C., Carducci, M.A., Egan, J., & Dobs, A.S. (2006). Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer, 106, 581-588.
5. Baselga, J., Campone, M., Piccart, M., Burris, H.A., III, Rugo, H.S., Sahmoud, T., ... Hortobagyi, G.N. (2012). Everolimus in post menopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine, 366, 520-529.
6. Beer, T.M., Ryan, C.W., Venner, P.M., Petrylak, D.P., Chatta, G.S., Ruether, J.D., ... Clow, F.W. (2007). Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. Journal of Clinical Oncology, 25, 669-674.
7. Bellmunt, J., Szczylik, C., Feingold, J., Strahs, A., & Berkenblit, A. (2008). Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology, 19, 1387-1392.
8. Bex, A., Mallo, H., Kerst, M., Haanen, J., Horenblas, S., & de Gast, G.C. (2005). A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunology, Immunotherapy, 54, 713-719.
9. Braga-Basaria, M., Dobs, A.S., Muller, D.C., Carducci, M.A., John, M., Egan, J., & Basaria, S. (2006). Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Journal of Clinical Oncology, 24, 3979-3983.
10. Brunello, A., Kapoor, R., & Extermann, M. (2011). Hyperglycemic dur ing chemotherapy for hematologic and solid tumors is correlated with increased toxicity. American Journal of Clinical Oncology, 34, 292-296. doi:10.1097/coc.0b013e3181e1d0c0
11. Derweesh, I.H., Diblasio, C.J., Kincade, M.C., Malcolm, J.B., Lamar, K.D., Patterson, A.L., ... Wake, R.W. (2007). Risk of new-onset dia betes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU International, 100, 1060-1065.
12. Feliu, J., Martin, G., Lizon, J., Chacon, J.I., Dorta, J., de Castro, J., ... Gonzalez Baron, M. (2001). Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study. Annals of Oncology, 12, 1369-1374.
13. Feng, J.P., Yuan, X.L., Li, M., Fang, J., Xie, T., Zhou, Y., ... Ye, D.W. (2012). Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: Results from a single centre cohort study. Colorectal Disease, 17, 1463-1318.
14. Fuji, S., Kim, S., Mori, S., Fukuda, T., Kamiya, S., Yamasaki, S., ... Takaue, Y. (2007). Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing my eloablative allogeneic hematopoietic stem cell transplantation. Transplantation, 84, 814-820.
15. Fury, M.G., Sherman, E., Haque, S., Korte, S., Lisa, D., Shen, R., ... Pfister, D. (2012). A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 69, 591-598.
16. Galanis, E., Buckner, J.C., Maurer, M.J., Kreisberg, J.I., Ballman, K., Boni, J., ... Walsh, D.J. (2005). Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study. Journal of Clinical Oncology, 23, 5294-5304.
17. Giovanucci, E., Harlan, D., Archer, M., Bergenstal, R., Gapstur, S., Habel, L., ... Yee, D. (2010). Diabetes and cancer: A consensus report. CA: A Cancer Journal for Clinicians, 60, 207-221.
18. Godbout, J.P., & Glaser, R. (2006). Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer. Journal of Neuroimmune Pharmacology, 1, 421-427.
19. Grivennikov, S.I., & Karin, M. (2011). Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take the stage. Annals of the Rheumatic Diseases, 70(Suppl. 1), i104-i108.
20. Hakimian, P., Blute, M., Jr., Kashanian, J., Chan, S., Silver, D., & Shab sigh, R. (2008). Metabolic and cardiovascular effects of androgen deprivation therapy. BJU International, 102, 1509-1514.
21. Hammer, M.J., Casper, C., Gooley, T.A., O'Donnell, P.V., Boeckh, M., & Hirsch, I.B. (2009). The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biology of Blood and Marrow Transplantation, 15, 344-351.
22. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., ... Motzer, R.J. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine, 356, 2271-2281.
23. Inaba, M., Otani, Y., Nishimura, K., Takaha, N., Okuyama, A., Koga, M., ... Kasayama, S. (2005). Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism, 54, 55-59.
24. Infante, J.R., Yardley, D.A., Burris, H.A., III, Greco, F.A., Farley, C. P., Webb, C., ... Hainsworth, J.D. (2009). Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clinical Breast Cancer, 9, 23-28.
25. Jenkins, D.J., Kendall, C.W., Augustin, L.S., Franceschi, S., Hamidi, M., Marchie, A., ... Axelsen, M. (2002). Glycemic index: Overview of implications in health and disease. American Journal of Clinical Nutrition, 76, 266S-273S.
26. Katz, A. (2007). Modulation of glucose transport in skeletal muscle by reactive oxygen species. Journal of Applied Physiology, 102, 1671-1676.
27. Leak, A., Davis, E., Houchin, L., & Mabrey, M. (2009). Diabetes management and self-care education for hospitalized patients with cancer. Clinical Journal of Oncology Nursing, 13, 205-210.
28. Lee, Y.J., Doliny, P., Gomez-Fernandez, C., Powell, J., Reis, I., & Hur ley, J. (2004). Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. Clinical Breast Cancer, 5, 371-376.
29. Lim, T., Lee, J., Lee, D., Lee, H., Han, B., Baek, K., ... Kim, W. (2011). Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemotherapy and Pharmacology, 68, 255-262.
30. Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454, 436-444.
31. Martin-Salces, M., de Paz, R., Canales, M.A., Mesejo, A., & Hernan dez-Navarro, F. (2008). Nutritional recommendations in hemato poietic stem cell transplantation. Nutrition, 24, 769-775.
32. Meyerhardt, J., Catalano, P., Haller, D., Mayer, R., Macdonald, J., Ben son A., III, & Fuchs, C. (2003). Impact of diabetes on outcomes in patients with colon cancer. Journal of Clinical Oncology, 21, 443-440.
33. Moien-Afshari, F., Ghosh, S., Khazaei, M., Kieffer, T.J., Brownsey, R.W., & Laher, I. (2008). Exercise restores endothelial function independently of weight loss or hyperglycaemic status in db/db mice. Diabetologia, 51, 1327-1337. doi:10.1007/s00125-008-0996-x
34. Moretti, M., Bennett, J., Tornatore, L., Thotakura, A.K., & Franzoso, G. (2012). Cancer: NF-kappaB regulates energy metabolism. International Journal of Biochemistry and Cell Biology, 10, 10.
35. Naing, A., Kurzrock, R., Burger, A., Gupta, S., Lei, X., Busaidy, N., ... LoRusso, P. (2011). Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clinical Cancer Research, 17, 6052-6060.
36. National Institutes of Health. (2010). National diabetes statistics, 2011. Retrieved from http://diabetes.niddk.nih.gov/dm/PUBS/statis tics/DM-Statistics-508.pdf
37. Okabe, S., Ishikawa, T., Tanami, H., Kuwabara, H., Fukahara, T., Udagawa, M., ... Iwai, T. (2002). Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. Journal of Medical and Dental Sci ences, 49, 77-84.
38. Psarakis, H. (2006). Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectrum, 19, 157-162.
39. Ribeiro, A.F., Camara, C., Segre, C.A., Srougi, M., & Serrano, C.V., Jr. (2010). Cardiovascular risks of androgen deprivation therapy. Arquivos Brasileiros De Cardiologia, 95, 412-415.
40. Richardson, L., & Pollack, L. (2005). Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nature Clinical Practice Oncology, 2, 48-53. doi:10.1038/ncponc0062
41. Roumen, C., Blaak, E.E., & Corpeleijn, E. (2009). Lifestyle interven tion for prevention of diabetes: determinants of success for future implementation. Nutrition Reviews, 67, 132-146.
42. Spigel, D.R., Greco, F.A., Meluch, A.A., Lane, C.M., Farley, C., Gray, J.R., ... Hainsworth, J.D. (2010). Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastro esophageal junction. Journal of Clinical Oncology, 28, 2213-2219. doi:10.1200/jco.2009.24.8773
43. Stookey, J.D., Pieper, C.F., & Cohen, H.J. (2004). Hypertonic hyper glycemia progresses to diabetes faster than normotonic hyperglycemia. European Journal of Epidemiology, 19, 935-944.
44. Storey, S., & Von Ah, D. (2012). Impact of malglycemia on clinical outcomes in hospitalized patients with cancer: A review of the literature. Oncology Nursing Forum, 39, 458-465. doi:10.1188/12.ONF.458-465
45. Turina, M., Christ-Crain, M., & Polk, H., Jr. (2006). Diabetes and hyperglycemia: Strict glycemic control. Critical Care Medicine, 34 (9, Suppl.), S291-S300.
46. U.S. Department of Health and Human Services. (2013). Aging statistics. Retrieved from http://www.aoa.gov/Aging-Statistics
47. Zeng, L., Biernacka, K., Holly, J., Jarrett, C., Morrison, A., Morgan, A., ... Perks, C. (2010). Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocrine-Related Cancer, 17, 539-551. doi:10.0677/ERC-09-0221